Skip to main content

Table 1 Baseline characteristics of the Taiwanese population in the GLOBE trial, 2303 study, and HBV DNA kinetics analysis

From: Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

Characteristic GLOBE trial Study 2303 HBV DNA reduction kinetics study HBeAg-positive patients from GLOBE
HBeAg- positive (n = 16) HBeAg- negative (n = 25) HBeAg- positive (n = 16) HBeAg- negative (n = 25) ≤5 log10 copies/mL at Week 24 (n = 8) >5 log10 copies/mL at Week 24 (n = 26) P value
Age (years)        
 Median (min–max) 27.5 (19–53) 45.0 (20–63) 29.5 (21–55) 47.0 (22–65) 38.0 (20–45) 27.5 (19–56)  
 Age range, n (%)        
  <30 9 (56.3) 1 (4.0) 8 (50.0) 1 (4.0) 3 (37.5) 15 (57.7)  
  30–50 6 (37.5) 19 (76.0) 7 (43.8) 17 (68.0) 5 (62.5) 8 (30.8) 0.223
  >50 1 (6.3) 5 (20.0) 1 (6.3) 7 (28.0) 0 (0) 3 (11.5)  
Gender        
 Male, n(%) 11 (68.8) 21 (84.0) 11 (68.8) 21 (84.0) 5 (62.5) 19 (73.1) 0.566
 Female, n(%) 5 (31.3) 4 (16.0) 5 (31.3) 4 (16.0) 3 (37.5) 7 (26.9)  
Weight        
 Median (min–max) 67.5 (48–95) 68.0 (42–95) 69.5 (51–92) 65.5 (43–91) 61.5 (49–73) 67.5 (38–95)  
HBV genotype, n(%)        
 B 13 (81.3) 17 (68.0) 13 (81.3) 17 (68.0) 5 (62.5) 16 (61.5)  
 C 3 (18.8) 8 (32.0) 3 (18.8) 8 (32.0) 3 (37.5) 10 (38.5) 0.961
HBV DNA (log 10 copies/mL)        
 Median (min–max) 10.2 (7–13) 7.2 (4–13) 2.5 (2–10) 2.2 (2–5) 8.9 (6–10) 10.2 (8–15)  
ALT (U/L)        
 Median (min–max) 134.5 (51–288) 110.0 (40–499) 27.5 (10–272) 29.0 (15–63) 92.0 (53–231) 149.0 (43–767)